The Feinstein Institutes for Medical Research

The Picower Institute for Medical Research

North Shore-long Island Jewish Research Institute

University of Pittsburgh

The General Hospital Corporation

Cytokine Pharmasciences, Inc.

Other

Kevin J Tracey

Haichao Wang

Anthony Cerami

Peter C Ulrich

Marina Bianchi

Sangeeta S Chavan

Huan Yang

Jared M Huston

Mitchell P Fink

Howland Shaw Warren

Richard J Bucala

Yousef Al-Abed

Wei Li

Helen Vlassara

Hong Wang

Christopher J Czura

Valentin A Pavlov

Michael I Bukrinsky

Pamela Cohen

Andrew E Sama

Helena Schmidtmayerova

Michael Allen Faltys

Ping Wang

Minghuang Zhang

Mauricio Rosas-Ballina

Seema G Amin

Jason R Fritz

Adam M Kressel

William Hanes

Carol Ann Amella

William R Parrish

Ralph J Zitnik

Timothy R Billiar

Christine N Metz

Jianhua Li

Chad Edward Bouton

Russell L Delude

Svetlana Ivanova

Peder Olofsson

Harold Silverman

Emily Battinelli

Lihong Yang

Todd Levy

Theodoros Zanos

Jian Hua Li

Andrew Stiegler

Allan Tsung

Haicho Wang

Luis Ulloa

Methods are presented for treating a subject having a disease or disorder comprising stimulating a vagus nerve of the subject with a corrective stimulus pattern derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific vagus neurogram in an amount and manner effective to treat the disease or disorder in a subject.

Nerve stimulation for treatment of diseases and disorders

Compositions and methods are provided comprising choline acetyltransferase (ChAT) and PEGylated ChAT for treating hypertension.

Choline acetyltransferase as a therapy for hypertension

Disclosed are apparatuses and methods for reducing or limiting bleeding (e.g., blood loss and/or bleeding time) in an animal by trigeminal stimulation. The apparatuses and methods may activate one or more branches of the trigeminal nerve. This activation may be invasive or non-invasive.

Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation

The present disclosure relates to systems, methods and devices to monitor, diagnose and/or treat diseases or disorders comprising a calibration phase and a real-time diagnostic, treatment or monitoring phase, the calibration phase correlating a plurality of nerve activity measurements from a chronically implanted electrode in a subject with a plurality of concurrent measurements of levels of cytokines and/or glucose in the blood to obtain a functional relationship between blood cytokine and/or glucose levels and vagus nerve activity, and the diagnostic, treatment or monitoring phase analyzing the subject's real-time vagus nerve activity in accordance with the previously obtained functional relationship to initiate a treatment method.

Systems and methods for real-time monitoring of physiological biomarkers through nerve signals and uses thereof

Methods for electrical modulation of inflammation or serum TNF levels in a subject.

Treatment of inflammation by selective DMV cholinergic neuron stimulation

Methods of treating HMGB1-mediated inflammation by administering a therapeutically effective amount of an MD2-antagonist to a subject in need thereof are described. The novel MD2 antagonist tetrapeptide P5779 is also described.

Treatment of HMGB1-mediated inflammation

Methods are disclosed for treating a subject having a disease or disorder comprising stimulating a nerve of the subject with a corrective stimulus pattern derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.

A method and an apparatus for treating a patient suffering from, or at risk for, a condition mediated by the inflammatory cytokine cascade, by electrically stimulating vagus nerve activity in an amount sufficient to inhibit the inflammatory cytokine cascade.

Treating inflammatory disorders by electrical vagus nerve stimulation

Provided are CD4+ T-cell-based compositions and methods for treating hypertension.

Methods of treating hypertension

Methods are disclosed for treating a subject having a disease or disorder comprising providing the subject with an acoustic energy stimulus derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.

Bioelectronic pharmaceuticals

Described herein are methods for treating a subject suffering from or at risk for a condition mediated by an inflammatory cytokine cascade, by electrically or mechanically stimulating vagus nerve activity in an amount sufficient to inhibit the inflammatory cytokine cascade.

Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway

A method of treating a disease or reducing the development of a symptom of a disease in a subject by administering to the subject an amount of tetranectin protein or a tetranectin peptide agonist effective to treat or reduce development of the disease or disease symptom.

Use of tetranectin and peptide agonists to treat inflammatory diseases

Methods of treating sepsis or endotoxemia in a subject comprising administering to the subject an amount of an antagonist of a Panx1 hemichannel protein or an amount of an antagonist of a Cx43 hemichannel protein.

Hemichannel extracellular-domain specific agents for treating ischemia-reperfusion injury

Growing community of inventors

Old Greenwich, CT, United States of America

Kevin J Tracey